Who to call at Salarius Pharmaceuticals, Inc., and when
Fundz watches for the moments Salarius Pharmaceuticals, Inc. starts buying, and tells you who to reach.
- An alert the day Salarius Pharmaceuticals, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Salarius Pharmaceuticals, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Salarius Pharmaceuticals, Inc.. With Fundz connected, it knows.
Salarius Pharmaceuticals, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
salariuspharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
Salarius Pharmaceuticals closed a public offering on November 12, 2025, raising approximately $6.3 million in net proceeds at $1.50 per share with accompanying Series A and Series B warrants. The filing also reports leadership changes tied to the merger, with Frederick E. Pierce named CEO and Board director and new Chief Scientific and Chief Business Officers.
Key Takeaways
The offering sold 2,514,335 common shares plus pre-funded warrants for up to 2,152,331 shares, with a combined public offering price of $1.50 per share and $1.4999 per pre-funded warrant, before under
Series A and Series B warrants for up to 4,666,666 shares each were issued, and the underwriter's option was exercised for 665,729 additional shares plus matching warrants, which creates significant f
3 more takeaways
Related Filings (11)
11 more filings from Salarius Pharmaceuticals, Inc. in the last 90 days
Filing Overview
What This Means
Salarius Pharmaceuticals, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.